Genetic Engineering

Genetic engineering uses laboratory methods to alter an organism's DNA. Changes can involve a single DNA base, removal of a segment, or insertion of genetic material. Its applications extend beyond medicine to industrial organisms and agriculture; this page focuses on its place within Iran's medical biotechnology research. The National Human Genome Research Institute's glossary provides the underlying definition. s1

Genome editing is a more targeted application of this broader field. Editing tools allow researchers to change selected DNA sites, using cellular repair processes after a targeted intervention. CRISPR is one family of tools used for this purpose. Researchers can also use editing to investigate what a gene does, rather than to develop a treatment directly. A laboratory experiment that changes a disease-related gene therefore needs to be understood in terms of its actual objective and experimental setting. s2

[s1] [s2]

A study involving Shahid Chamran University of Ahvaz and the Thalassemia and Hemoglobinopathy Research Center at Ahvaz Jundishapur University of Medical Sciences investigated CRISPR editing of a mutation in HBB, the gene encoding beta-globin. Beta-globin is a component of hemoglobin, the blood protein implicated in beta-thalassemia. The paper was published online in July 2025 and appeared in a 2026 journal issue. s3

The inspected abstract describes a proof-of-concept experiment targeting the mutation designated FSC 36/37 (-T). Researchers designed guide RNAs, tested constructs in a laboratory cell line, and subsequently investigated editing in isolated blood-forming stem cells. Their approach used homology-directed repair, a cellular repair pathway that can use a supplied DNA template. s3

This is evidence of an experimental editing project involving Iranian institutions. It does not establish that participants received edited cells, that their disease improved, or that a treatment obtained authorization. The abstract reports cellular findings; those findings should not be recast as a clinical success rate. Detailed assessment of the methods and reproducibility requires the full paper. s3

[s3]

A central distinction concerns which cells are changed. Somatic editing targets non-reproductive cells and is intended to affect the treated individual. Germline changes involve reproductive cells and may be inherited. These raise different scientific and ethical questions; evidence for one application cannot establish the acceptability or performance of the other. s2

Target specificity also matters. Editing tools can act at unintended locations, so detecting the intended DNA change is only part of evaluating an intervention. Delivery, unintended effects, and patient safety remain separate questions. For readers following Iran's research, the useful distinction is between a promising molecular experiment and a clinically demonstrated intervention. The Ahvaz study supports the former description; the inspected evidence does not establish the latter. s2s3

[s2] [s3]